Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track ...

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study ...

Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data

Bicara Therapeutics (BCAX) just put fresh clinical data in the spotlight, with a Phase 1b expansion cohort of ficerafusp alfa plus pembrolizumab in first line HPV negative head and neck cancer earning ...
Pharmabiz

Rondo Therapeutics begins patient dosing in phase 1/1b trial of RNDO-564 in adults with r/r locally advanced or metastatic urothelial carcinoma

Rondo Therapeutics begins patient dosing in phase 1/1b trial of RNDO-564 in adults with r/r locally advanced or metastatic urothelial carcinoma: Hayward, California Saturday, Dece ...
Targeted Oncology

Poll: Vote on the Top Abstracts to Watch at SABCS 2025

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...

Liver Cancer Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Eli Lilly, Merck, Genetech, GlaxoSmithKline, Bristol-Myers Squibb

In November 2025, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology firm specializing in therapies for primary ...